A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s blockbuster weight loss and diabetes drugs from its shortage list last week,

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.

Eli Lilly’s blockbuster obesity and diabetes drugs Zepbound and Mounjaro are no longer in shortage, according to the Food and Drug Administration.It’s a sign that pharmaceutical firm Lilly is making strides to improve the supply issues that have plagued the sector.